DSIP (Delta Sleep-Inducing Peptide): Benefits, Dosage, and How to Get It in 2026

What is DSIP?

DSIP is a small, naturally occurring neuropeptide first identified in research on sleep. The name describes the effect observed in early studies: it promotes delta-wave (slow-wave) sleep, the deepest stage of non-REM sleep.

In a compounding-pharmacy context it is referred to as Emideltide. DSIP occurs naturally in the body, and it is not FDA-approved as a drug in the United States.

Benefits and uses

What the research has examined — with the honest caveat that human clinical data is limited:

• Sleep regulation. The most-studied effect; DSIP promotes slow-wave sleep in research settings and has been investigated for sleep disturbances.
• Stress resilience. Studied for effects on the stress response and adaptation.
• Pain modulation. Some research has looked at a possible role in pain perception.
• Hormone regulation. Investigated for possible effects on hormone release, though this is not well established.

State the limit plainly: DSIP has a research history spanning decades, but rigorous, large-scale human clinical trials are limited, and several of its proposed effects are not firmly established.

How it works

DSIP's mechanism is not fully understood. In research it promotes slow-wave (delta) sleep and appears to interact with systems that regulate the stress response and circadian rhythm, but the exact receptors and pathways it acts through have not been definitively mapped.

This is an honest gap rather than a settled mechanism — the peptide is named for an observed effect, not a fully characterized pathway.

Dosage and administration

DSIP is administered by subcutaneous injection. There is no FDA-approved DSIP product and no official dosing guideline. Protocols vary, and DSIP is typically used in the evening given its sleep-related effects. Dosing should be set by a prescribing provider.

Use the peptide dosage calculator to convert a target dose into the right volume for your vial size.

Side effects and safety

DSIP is generally reported to be well tolerated in research, with few reported adverse effects. Because it occurs naturally and has been studied for decades, acute tolerability appears favorable, but long-term human safety data is limited. Anyone using DSIP should work with a provider and establish a safety baseline.

How to get DSIP in 2026

The regulatory status changed this year:

• For several years DSIP sat on the FDA's Section 503A Category 2 list, which effectively blocked compounding pharmacies from preparing it.
• On April 15, 2026 the FDA removed DSIP (as Emideltide, and 11 other peptides) from that Category 2 list.
• A Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026 will evaluate whether Emideltide (DSIP) should be formally added to the authorized bulk-substances list compounding pharmacies can use.

Until that process completes, the cleanest legal route is a prescription filled by a licensed compounding pharmacy. Products sold online "for research use only" are not manufactured or quality-controlled for human use, and buying them carries both quality and legal risk.

Rite Aid is preparing compounded peptide consultations. Join the waitlist to claim 20% off your first DSIP order when consultations and ordering open.

DSIP vs other sleep and longevity peptides

DSIP is often considered alongside other peptides used for recovery and longevity protocols. It is compared with Epitalon, studied for melatonin and circadian regulation, and grouped with Semax in the broader research-peptide set.

For a longer-term protocol, compare DSIP with other anti-aging and longevity peptides.

Blood work to track DSIP

DSIP doesn't have a single direct biomarker, so tracking focuses on safety:

• Comprehensive metabolic profile — liver enzymes and kidney function, the safety baseline for any peptide cycle.

Test before you start and again at 4–6 weeks.